Vertex Pharmaceuticals | VRTX - Assets



Vertex Pharmaceuticals reported $24.04B in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
AbbVie USD 136.17B 1B Mar/2025
Acadia Pharmaceuticals USD 1.23B 93.19M Jun/2025
Agios Pharmaceuticals USD 1.47B 84.28M Jun/2025
Alnylam Pharmaceuticals USD 4.57B 352.21M Jun/2025
Amgen USD 87.9B 1.47B Jun/2025
Arrowhead Research USD 1.38B 192.89M Jun/2025
Biogen USD 28.33B 297.1M Jun/2025
BioMarin Pharmaceutical USD 7.46B 309.33M Jun/2025
Bristol-Myers Squibb USD 94.68B 2.25B Jun/2025
Gilead Sciences USD 55.72B 713M Jun/2025
Incyte USD 5.82B 71.99M Jun/2025
Insmed USD 2.48B 677.12M Jun/2025
Ionis Pharmaceuticals USD 2.99B 172.18M Jun/2025
J&J USD 193.67B 13.57B Mar/2025
Merck USD 117.52B 2.4B Jun/2025
Moderna USD 12.01B 694M Jun/2025
Neurocrine Biosciences USD 3.89B 202.1M Jun/2025
Novartis USD 104.4B 4.45B Jun/2025
Pfizer USD 206.1B 1.93B Jun/2025
PTC Therapeutics USD 2.63B 21.23M Jun/2025
Regeneron Pharmaceuticals USD 38.22B 674M Jun/2025
Roche Holding CHF 101.8B 6.02B Dec/2024
Sanofi 124.96B 6.93B Jun/2025
Sarepta Therapeutics USD 3.68B 214.43M Jun/2025
Ultragenyx Pharmaceutical USD 1.31B 5.66M Jun/2025
United Therapeutics USD 7.91B 164.1M Jun/2025
Vertex Pharmaceuticals USD 24.04B 1.16B Jun/2025